The first patients have been enrolled in the single-centre DEPPER LIMUSclinical trial, Reflow Medical has announced. The non-randomised pilot study will evaluate the temporary spur stent system for the treatment of lesions in the infrapopliteal arteries using a limus-base drug-coated balloon.
According to the company, the DEEPER LIMUS study is expected to enrol up to 30 patients for approximately six months at a single centre outside the USA. It will follow primary and secondary endpoints for safety and efficacy.
“This gives us an opportunity to truly understand how differently antirestenotic drugs can treat infrapopliteal disease,” the trial’s principal investigator Marianne Brodmann (Medical University of Graz, Graz, Austria) comments. “The unique design of the spur device may enable the antiproliferative drug to reach the medial layers of the arterial wall, without leaving anything behind, and minimising the need for follow-up procedures.”
The retrievable temporary spur stent system is designed to treat long, diffuse, and severely calcified infrapopliteal disease. The device has a series of radially expandable spikes intended to create multiple pathways to allow the increased uptake of antiproliferative drugs into the vessel wall and facilitate acute luminal gain, without leaving anything behind, state Reflow Medical.
Source VascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389